Identification

Summary

Polidocanol is a sclerosing agent used for the treatment of uncomplicated spider veins and uncomplicated reticular veins, all less than 3 mm in diameter, in the lower extremity.

Brand Names
Asclera, Varithena
Generic Name
Polidocanol
DrugBank Accession Number
DB06811
Background

Polidocanol is a sclerosing agent indicated to treat uncomplicated spider veins (varicose veins ≤1 mm in diameter) and uncomplicated reticular veins (varicose veins 1 to 3 mm in diameter) in the lower extremity. It is marketed under the brand names Asclera and Varithena. The formula for Polidocanol has the structural formula C12H25(OCH2CH2)nOH, a mean extent of polymerization (n) of approximately 9 and a mean molecular weight of approximately 600.

Type
Small Molecule
Groups
Approved
Structure
Thumb
Weight
Average: 582.8073
Monoisotopic: 582.434298204
Chemical Formula
C30H62O10
Synonyms
  • Aethoxy-sklerol
  • Laureth 9
  • Laureth-9
  • Macrogol 9 lauryl ether
  • Nonaethylene glycol monododecyl ether
  • Nonaethylene glycol monolauryl ether
  • PEG-9 lauryl ether
  • Polidocanol
  • Polydocanol
  • Polyethylene glycol 450 lauryl ether
  • Polyoxyl 9 lauryl ether
External IDs
  • 3055-99-0

Pharmacology

Indication

Polidocanol is a sclerosing agent indicated to treat uncomplicated spider veins and uncomplicated reticular veins in the lower extremity.

Pharmacology
Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Associated Conditions
Contraindications & Blackbox Warnings
Contraindications
Avoid life-threatening adverse drug events
Improve clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events & improve clinical decision support.
Learn more
Pharmacodynamics

Polidocanol has a concentration and volume dependent damaging effect on the blood vessel endothelium.

Mechanism of action

When administered, polidocanol locally damages blood vessel endothelium. Following the endothelial damage, platelets aggregate at the site and attach to the venous wall eventually resulting in a dense network of platelets, cellular debris, and fibrin that occludes the vessel. Eventually the vessel is replaced by connective fibrous tissue.

Absorption

When given intravenously, the maximum blood concentrations were reached in 15 mins.

Volume of distribution

When given intravenously, the volume of distribution was 35-82L.

Protein binding

Plasma protein binding was not measured.

Metabolism

Metabolism was not measured.

Route of elimination

Route of elimination was not indicated.

Half-life

The half-life is approximately 1.5 h.

Clearance

Sytemic clearance was 0.2-0.4 L/min.

Adverse Effects
Adverseeffects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.
Learn more
Improve decision support & research outcomes with our structured adverse effects data.
Learn more
Toxicity

Most adverse reactions are related to the intravenous administration such as local irritation, pain, and hematoma. Extravasation can also be an issue.

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
Antihemophilic factor (recombinant), PEGylatedThe therapeutic efficacy of Antihemophilic factor (recombinant), PEGylated can be decreased when used in combination with Polidocanol.
Certolizumab pegolThe therapeutic efficacy of Certolizumab pegol can be decreased when used in combination with Polidocanol.
Damoctocog alfa pegolThe therapeutic efficacy of Damoctocog alfa pegol can be decreased when used in combination with Polidocanol.
ElapegademaseThe therapeutic efficacy of Elapegademase can be decreased when used in combination with Polidocanol.
LipegfilgrastimThe therapeutic efficacy of Lipegfilgrastim can be decreased when used in combination with Polidocanol.
Methoxy polyethylene glycol-epoetin betaThe therapeutic efficacy of Methoxy polyethylene glycol-epoetin beta can be decreased when used in combination with Polidocanol.
Nonacog beta pegolThe therapeutic efficacy of Nonacog beta pegol can be decreased when used in combination with Polidocanol.
PegademaseThe therapeutic efficacy of Polidocanol can be decreased when used in combination with Pegademase.
PegaptanibThe therapeutic efficacy of Polidocanol can be decreased when used in combination with Pegaptanib.
PegaspargaseThe therapeutic efficacy of Polidocanol can be decreased when used in combination with Pegaspargase.
Interactions
Identify potential medication risks
Easily compare up to 40 drugs with our drug interaction checker.
Get severity rating, description, and management advice.
Learn more
Food Interactions
No interactions found.

Products

Products2
Drug product information from 10+ global regions
Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.
Access now
Access drug product information from over 10 global regions.
Access now
International/Other Brands
Aethoxysklerol
Brand Name Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing EndRegionImage
AscleraInjection, solution0.01000 g/1mLIntravenousMerz North America, Inc2010-06-012022-08-31US flag
AscleraInjection, solution0.00500 g/1mLIntravenousMerz North America, Inc2010-06-012022-08-31US flag
VarithenaKit10 mg/1mLIntravenousBiocompatibles, Inc.2013-11-25Not applicableUS flag
VarithenaKit10 mg/1mLIntravenousBiocompatibles, Inc.2017-12-22Not applicableUS flag
VarithenaKit1.3 mg / mLIntravenousProvensis Ltd2016-11-30Not applicableCanada flag
VarithenaKit10 mg/1mLIntravenousBiocompatibles, Inc.2014-07-10Not applicableUS flag
VarithenaKit10 mg/1mLIntravenousBiocompatibles, Inc.2014-07-102017-01-09US flag
VarithenaKit10 mg/1mLIntravenousBiocompatibles, Inc.2017-12-22Not applicableUS flag
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing EndRegionImage
DENTINOX 3.4 MG/G + 3.2 MG/G + 150 MG/G JEL, 10 GPolidocanol (3.2 mg/g) + Chamaemelum nobile flower (150 mg/g) + Lidocaine hydrochloride (3.4 mg/g)GelOralABDİ İBRAHİM İLAÇ SAN. VE TİC. A.Ş.2020-08-14Not applicableTurkey flag
DENTINOX 3.4 MG/G + 3.2 MG/G + 150 MG/G JEL, 20 GPolidocanol (3.2 mg/g) + Chamaemelum nobile flower (150 mg/g) + Lidocaine hydrochloride (3.4 mg/g)GelOralABDİ İBRAHİM İLAÇ SAN. VE TİC. A.Ş.2020-08-14Not applicableTurkey flag
KORTOS 27 MG/ 5 MG SUPOZITUAR, 10 ADETPolidocanol (5 mg) + Hydrocortisone acetate (27 mg)SuppositoryRectalEXELTIS İLAÇ SAN. VE TİC. A.Ş.2020-08-14Not applicableTurkey flag
SOLCOSERYL ADHEZIV DIS PATI, 5 GPolidocanol (10 mf) + Solcoseryl (2 mg)PatchOralMEDA PHARMA İLAÇ SAN. VE TİC. LTD. ŞTİ.2020-08-14Not applicableTurkey flag
SOLCOSERYL DENTAL ADHESIVE PASTEPolidocanol (10 mg/g) + Solcoseryl (2.125 mg/g)PasteDentalA. MENARINI SINGAPORE PTE. LTD.2020-09-08Not applicableMalaysia flag
คอลโลแม็คPolidocanol (2 G/100G) + Lactic acid (5 G/100G) + Salicylic acid (20 G/100G)SolutionTopicalบริษัท แอสมีโก้ (ประเทศไทย) จำกัด2006-12-29Not applicableThailand flag

Categories

ATC Codes
C05BB02 — Polidocanol
Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as polyethylene glycols. These are oligomers or polymers of ethylene oxide, with the general formula (C2H4O)n (with n>=3).
Kingdom
Organic compounds
Super Class
Organic oxygen compounds
Class
Organooxygen compounds
Sub Class
Ethers
Direct Parent
Polyethylene glycols
Alternative Parents
Primary alcohols / Hydrocarbon derivatives
Substituents
Alcohol / Aliphatic acyclic compound / Hydrocarbon derivative / Polyethylene glycol / Primary alcohol
Molecular Framework
Aliphatic acyclic compounds
External Descriptors
hydroxypolyether (CHEBI:46859)
Affected organisms
  • Humans and other mammals

Chemical Identifiers

UNII
0AWH8BFG9A
CAS number
9002-92-0
InChI Key
ONJQDTZCDSESIW-UHFFFAOYSA-N
InChI
InChI=1S/C30H62O10/c1-2-3-4-5-6-7-8-9-10-11-13-32-15-17-34-19-21-36-23-25-38-27-29-40-30-28-39-26-24-37-22-20-35-18-16-33-14-12-31/h31H,2-30H2,1H3
IUPAC Name
3,6,9,12,15,18,21,24,27-nonaoxanonatriacontan-1-ol
SMILES
CCCCCCCCCCCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO

References

General References
  1. Peterson JD, Goldman MP, Weiss RA, Duffy DM, Fabi SG, Weiss MA, Guiha I: Treatment of reticular and telangiectatic leg veins: double-blind, prospective comparative trial of polidocanol and hypertonic saline. Dermatol Surg. 2012 Aug;38(8):1322-30. doi: 10.1111/j.1524-4725.2012.02422.x. Epub 2012 May 23. [Article]
  2. Weiss RA, Voigts R, Howell DJ: Absence of concentration congruity in six compounded polidocanol samples obtained for leg sclerotherapy. Dermatol Surg. 2011 Jun;37(6):812-5. doi: 10.1111/j.1524-4725.2011.01906..x. [Article]
  3. Link [Link]
KEGG Drug
D01993
KEGG Compound
C13493
PubChem Compound
656641
PubChem Substance
175427093
ChemSpider
570993
RxNav
968170
ChEBI
46859
ChEMBL
CHEMBL1231723
ZINC
ZINC000008214662
PDBe Ligand
CE9
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
PDRhealth
PDRhealth Drug Page
Wikipedia
Polidocanol
PDB Entries
3dm8 / 5k9d
FDA label
Download (86.7 KB)
MSDS
Download (567 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
4CompletedTreatmentChronic Achilles Tendinopathy1
4CompletedTreatmentTelangiectasias / Varicosities of the great saphenous vein1
4CompletedTreatmentVaricosities of the great saphenous vein2
4Unknown StatusTreatmentCystic tumour of the ganglia1
4WithdrawnTreatmentReflux / Ulcers, Leg / Varicose Ulcers / Varicose veins of legs / Varicosities of the great saphenous vein / Venous Leg Ulcer (VLU) / Venous Reflux / Venous Ulcers1
3CompletedTreatmentGreat Saphenous Vein Incompetence / Visible Varicosities1
3CompletedTreatmentVaricosities of the great saphenous vein2
2CompletedTreatmentHemorrhoids Second Degree1
2CompletedTreatmentHemorrhoids, Internal1
2CompletedTreatmentVaricosities of the great saphenous vein2

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
FormRouteStrength
Injection, solutionIntravenous
Injection, solutionParenteral
SolutionParenteral10 mg/1ml
SolutionParenteral30 mg/1ml
Injection, solutionIntravenous0.00500 g/1mL
Injection, solutionIntravenous0.01000 g/1mL
Injection, solution
GelBuccal
GelOral
SolutionParenteral0.1 g
SolutionIntravenous0.3 g
SolutionParenteral0.3 g
SuppositoryRectal
SolutionTopical
CreamTopical
OintmentTopical
PatchOral
PasteDental
KitIntravenous1.3 mg / mL
KitIntravenous10 mg/1mL
InjectionIntravenous10 mg/ml
InjectionIntravenous3 %
Prices
Not Available
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)Region
US7814943No2010-10-192027-11-19US flag
US7842282No2010-11-302020-05-26US flag
US7604185No2009-10-202020-05-26US flag
US7357336No2008-04-152020-05-26US flag
US7025290No2006-04-112020-05-26US flag
US6572873No2003-06-032020-05-26US flag
US7731986No2010-06-082024-11-17US flag
USRE40640No2009-02-172016-10-14US flag
US8734833No2014-05-272020-05-26US flag
US8122917No2012-02-282024-09-09US flag
US6942165No2005-09-132020-05-26US flag
US8323677No2012-12-042020-05-26US flag
US6846412No2005-01-252022-07-19US flag
US7842283No2010-11-302020-05-26US flag
US9480652No2016-11-012032-05-12US flag

Properties

State
Liquid
Experimental Properties
PropertyValueSource
melting point (°C)33-36 °CNot Available
boiling point (°C)615.857 °C at 760 mmHgNot Available
water solubilitymiscible http://ec.europa.eu/health/ph_risk/committees/04_sccp/docs/sccp_o_113.pdf
logP3.94# http://www.chemicalize.org/structure/#!mol=polidocanol
Predicted Properties
PropertyValueSource
Water Solubility0.000403 mg/mLALOGPS
logP3.15ALOGPS
logP3.94ChemAxon
logS-6.2ALOGPS
pKa (Strongest Acidic)15.12ChemAxon
pKa (Strongest Basic)-2.7ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count10ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area103.3 Å2ChemAxon
Rotatable Bond Count37ChemAxon
Refractivity158.33 m3·mol-1ChemAxon
Polarizability74.51 Å3ChemAxon
Number of Rings0ChemAxon
Bioavailability0ChemAxon
Rule of FiveNoChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Download (10.2 KB)
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Drug created at September 14, 2010 16:21 / Updated at November 28, 2021 11:56